In addition to germline SNPs of tamoxifen-metabolizing genes, such as CYP19, CPY2D6, and SULT1A1 [8, 31–33], SNPs identified in genomewide association studies (GWAS) have been found to be associated with breast cancer risk [34, 35]. This evidence concerns the gene CYP19A1 and breast cancer.